Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

This was the stock's second consecutive day of losses.

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Zimmer Biomet Holdings (ZBH – Research Report).

Zimmer Biomet ZBH continues to gain from procedure strength, strong execution and solid momentum in innovation. Yet the stock ...

We came across a bullish thesis on Zimmer Biomet Holdings, Inc. (ZBH) on Twitter by QuestforYield. In this article, we will ...

Equities researchers at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for Zimmer Biomet in a report ...

Assetmark Inc. decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 67.7% in the 4th quarter, ...

Before making this announcement, Zimmer Biomet Holdings was easily earning enough to cover the dividend. This means that most of what the business earns is being used to help it grow. Looking ...

Paragon 2 (FNA) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976in connection with ...

Zimmer Biomet Holdings launched a new educational campaign targeting people living with joint pain. 1 The campaign is ...

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting its diverse portfolio of orthopedic and musculoskeletal innovations at the ...

New bone cement formulations designed for prosthesis fixation in arthroplasty and joint reconstruction procedures ...